Business Context and Reporting Period
This Form 8-K Current Report was filed by Compass Therapeutics, Inc. on September 10, 2020. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and the compensation arrangements associated with that appointment.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only financial data disclosed relates to director compensation:
- Director Cash Retainer: $50,000 annually for general availability and committee participation.
- Equity Award: Initial option to purchase 60,000 shares of common stock.
- Option Exercise Price: $5.00 per share.
- Vesting Schedule: Monthly vesting over four years.
Material Changes
The material change reported is the appointment of Brett Kaplan, M.D., to the Board of Directors, effective September 10, 2020. Dr. Kaplan was designated as a Class I director with a term expiring in 2021. He was appointed as a member and Chair of the Audit Committee and qualified as an "audit committee financial expert." Additionally, a press release issued on September 15, 2020, announced the promotion of Vered Bisker-Leib to Chief Operating Officer.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of material risks and contingencies. It is a procedural report regarding board composition and officer appointments.
Key Facts for Investor Verification
- Verify the independence status of the newly appointed director, Brett Kaplan, M.D.
- Confirm the total equity dilution impact of the 60,000 share option grant relative to the company's outstanding share count.
- Review the press release (Exhibit 99.1) for details regarding the promotion of the Chief Operating Officer.
- Note that this filing does not contain updated financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.